Search | Page 15 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Azacytidine for the treatment of myelodysplastic syndromes in the elderly.

    ... observation alone for patients with low-risk disease, lenalidomide for patients with 5q-syndrome, to 5-azacytidine (5-AZA) for ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.

    ... azacitidine , (2) decitabine , and (3) lenalidomide . Clinical results with each of these agents, plus results ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

    ... risk and no transfusion dependency, growth factors, and lenalidomide for patients with alteration of chromosome 5 and anemia ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Myelodysplastic syndromes in older adults.

    ... from curative treatment. Developments using the drugs lenalidomide , decitabine , and azacitidine have offered ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Current and future management options for myelodysplastic syndromes.

    ... and (ii) the emergence of US FDA-approved agents such as lenalidomide , azacitidine and decitabine . Prior to these ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. An update on the treatment of myelodysplastic syndromes.

    ... MDS, the novel antitumor immunomodulatory agent lenalidomide is approved for patients with del(5q), and two different ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.

    ... gene expression profile may predict response to lenalidomide in patients who lack the deletion of 5q31.1. Tools such as ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Myelodysplastic syndromes.

    ... diagnosis is 72 and the median survival is 2.5 years. Lenalidomide , azacitidine , and decitabine are all ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression.

    ... The probability of a complete cytogenetic response to lenalidomide was lower in mutated patients (0 of 7 v 12 of 24; P = .024). ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Interviews with the Experts Managing MDS With Supportive Care and Active Treatment

    ... agent in this group that also improves blood counts is lenalidomide (Revlimid®), but it has a different mechanism of action from ... agents and is categorized as an immunomodulatory agent. Lenalidomide has been shown to be best suited for a subset of MDS patients ...

    Interview last updated 09/22/2014 - 12:25pm.